Korea S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
14,330
KRW
+0.63%
+0.63%
-16.15%
Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
May 11, 2023 at 08:18 pm EDT
Anterogen.Co.,Ltd. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was KRW 1,542.92 million compared to KRW 1,666.49 million a year ago. Net income was KRW 37.35 million compared to net loss of KRW 2,607.69 million a year ago.
Basic earnings per share from continuing operations was KRW 4 compared to basic loss per share from continuing operations of KRW 273 a year ago. Diluted loss per share from continuing operations was KRW 2 compared to KRW 118 a year ago. Basic earnings per share was KRW 4 compared to basic loss per share of KRW 273 a year ago.
Diluted loss per share was KRW 2 compared to KRW 118 a year ago.
Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-11
CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
21-03-07
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment
21-03-04
CI
Anterogen.Co.,Ltd. announced that it has received KRW 12 billion in funding
20-04-23
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 12 billion in funding
20-04-22
CI
An unknown buyer acquired 3.37% stake in Anterogen.Co.,Ltd. for KRW 10 billion.
20-03-25
CI
Anterogen.Co.,Ltd. announced that it has received KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
19-11-06
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 4.9999992 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, NH Investment & Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm
19-10-24
CI
Anterogen.Co.,Ltd. announced that it has received KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
19-02-25
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 13.999979 billion in funding from EM-Tech. CO., LTD.
19-02-14
CI
Anterogen.Co.,Ltd. announced that it has received KRW 6 billion in funding
19-01-31
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 6 billion in funding
19-01-23
CI
Anterogen.Co.,Ltd. announced that it has received KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm
18-11-19
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 9.9992224 billion in funding from Samsung Securities Co. Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, and another investor
18-11-07
CI
Anterogen.Co.,Ltd. announced that it has received KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
18-10-30
CI
Anterogen.Co.,Ltd. announced that it expects to receive KRW 19.99925713 billion in funding from NH Investment & Securities Co., Ltd., Investment Arm, KB Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd., Investment Arm
18-10-03
CI
Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding
18-06-11
CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 16 billion in funding from a group of investors.
18-06-10
CI
EM-Tech Co., Ltd. announced that it has received KRW 14 billion in funding from Anterogen Co.,Ltd.
18-04-10
CI
Anterogen Co.,Ltd. announced that it has received KRW 18 billion in funding
18-04-10
CI
Anterogen Co.,Ltd. announced that it has received KRW 10 billion in funding from Company K Partners Limited
17-09-28
CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from Company K Partners Limited
17-09-25
CI
Anterogen Co.,Ltd. announced that it has received KRW 10 billion in funding from EM-Tech. Co., Ltd.
17-04-26
CI
EM-Tech. Co., Ltd. announced that it has received KRW 7.82 billion in funding from Anterogen Co.,Ltd.
17-04-25
CI
Anterogen Co.,Ltd. announced that it expects to receive KRW 10 billion in funding from EM-Tech. Co., Ltd.
17-04-24
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.
More about the company
1st Jan change
Capi.
-16.15% 101M -4.66% 86.13B +1.32% 39.82B -19.27% 30.42B +57.86% 25.23B -16.09% 15.36B -9.14% 11.95B -17.69% 11.6B -43.00% 11.51B +5.24% 8.71B
Biopharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
ANTEROGEN.CO.,LTD. 
